Boehringer Ingelheim and F-star, an antibody engineering company based in Vienna, Austria, have entered a collaboration and license agreement for the discovery of new antibody-derived therapeutic products using F-star’s Modular Antibody Technology. Boehringer will select as many as seven targets, which may include multiple therapeutic areas, against which the two companies will work to discover Fcabs for further development and commercialization by Boehringer, either as therapeutic products or a...